ÁñÁ«ÊÓƵ

This pooled analysis of 6 clinical trials describes the safety and efficacy of different courses of immune checkpoint inhibitor treatment in a neoadjuvant setting among patients with high-risk resectable melanoma.

This retrospective analysis of data from 3 randomized clinical trials examines the association of pathologic complete response with event-free survival by intrinsic subtype and other gene expression signatures in patients with ERBB2/HER2-positive early breast cancer treated in the neoadjuvant setting

This study develops and validates machine learning approaches based on daily step counts collected by wearable devices in 3 prospective trials to predict hospitalizations during chemoradiotherapy.

This cohort study investigates the association between measured physical activity and Eastern Cooperative Oncology Group Performance Status, as well as the potential prognostic value of physical activity measurements in patients with advanced lung cancer.

This JAMA Oncology Patient Page explains artifical intelligence and what patients should know about how it can be used in oncology.

This essay describes how a dog played a role in one physicians process of being diagnosed with hepatocellular carcinoma.

This meta-analysis investigates the association of neoadjuvant chemoimmunotherapy with patient benefits vs neoadjuvant chemotherapy in patients with non–small cell lung cancer (NSCLC).

This study investigates the geographical distribution of self-identified racial and socioeconomic demographics within commuting distance to cancer clinical trial centers and other hospitals.

This narrative review summarizes the literature supporting the use of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for breast cancer treatment, as well as potential future research directions.

This Viewpoint suggests that giving patients with terminal cancer unrealistic hope based only on cure is ethically inferior to redirecting patients toward noncurative goals and noncancer-related hope.

This randomized clinical trial aims to determine if hypofractionated postprostatectomy radiotherapy is noninferior to conventionally fractionated postprostatectomy for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.

The quality improvement study examines the use of risk-adaptive adjuvant radiotherapy in women with non–mismatch repair deficiency endometrial cancer.

This Viewpoint discusses cancer antigen expression and antibody drug conjugates.

This nonrandomized clinical trial examines the toxicity and efficacy of stereotactic ablative radiotherapy in patients with interstitial lung disease and early-stage non–small cell lung cancer.

This study examines 2 randomized clinical trials to assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer.

This Viewpoint discusses whether select patient populations may benefit from de-escalation rather than escalation of systemic therapy for kidney cancer.